论文部分内容阅读
目的:探讨参与雌酮(Estrone,E1)和雌二醇(Estradiol,E2)相互转变的酶即17βHSD12、17βHSD7、17βHSD1、17βHSD2在乳腺良、恶性肿瘤组织内的表达及其与病理特点的关系。方法:采用RT-PCR方法测定17βHSD12、17βHSD7、17βHSD1、17βHSD2在48例女性乳腺良性及恶性肿瘤组织中的表达情况,并分析该类酶与临床病理参数的关系。结果:17βHSD12在乳腺癌组织高表达(96.96%),绝经后乳腺癌组织中的表达率为100.00%,与良性肿瘤组织表达率66.67%相比差异有统计学意义(P<0.05);17βHSD12表达率与癌组织雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体-2(Her-2)、淋巴结转移与否无关;17βHSD1、17βHSD7、17βHSD2在良、恶性肿瘤组织表达差异无统计学意义(P>0.05)。结论:17βHSD12与乳腺组织的恶性转化有关,有望成为乳腺癌内分泌治疗新靶点。
OBJECTIVE: To investigate the expression of 17βHSD12, 17βHSD7, 17βHSD1 and 17βHSD2, which are involved in the mutual transformation between estrone (E1) and estradiol (E2), in benign and malignant breast tissues and their relationship with pathological features. Methods: The expressions of 17βHSD12, 17βHSD7, 17βHSD1 and 17βHSD2 in 48 cases of benign and malignant breast cancer tissues were determined by RT-PCR. The relationship between these enzymes and clinicopathological parameters was analyzed. Results: 17βHSD12 was highly expressed in breast cancer tissues (96.96%) and 100.00% in postmenopausal breast cancer tissues, which was significantly different from that in benign tumor tissues (66.67%) (P <0.05). The expression of 17βHSD12 The expression of 17βHSD1, 17βHSD7, 17βHSD2 in benign and malignant tumors was significantly higher than that in normal tissues Tissue expression differences were not statistically significant (P> 0.05). Conclusion: 17βHSD12 is associated with the malignant transformation of breast tissue and is expected to become a new target of endocrine therapy in breast cancer.